Search Menu
Photonics Media Photonics Buyers' Guide Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook
More News

CTI Acquiring Concorde Microsystems

Facebook Twitter LinkedIn Email Comments
KNOXVILLE, Tenn., June 22 -- CTI Molecular Imaging Inc., a provider of positron emission tomography (PET) equipment, molecular imaging biomarkers and services, has announced a definitive agreement for the acquisition of Concorde Microsystems Inc., which makes small-animal PET systems for imaging laboratory animals used in medical research.

The transaction is structured as an asset purchase and is expected to close on June 30. The total consideration paid in connection with this acquisition is $41 million in cash and unregistered shares of CTI's common stock, plus the potential for incentive payments that are contingent on the future financial performance of Concorde Microsystems, which is partially owned and operated by the children of Ronald Nutt PhD, president and CEO of CTI Molecular Imaging.

CTI said the acquisition will increase its capabilities in the research and pharmaceutical markets. The company already supplies research isotopes and PET expertise to several pharmaceutical companies. In combination with its PETNET national network of radiopharmacies, CTI said, the acquisition will enable it to accelerate the discovery of new molecular imaging biomarkers for the clinical market.

"Concorde Microsystems has developed the premier technology for performing PET studies on laboratory animals used in basic and medical research. Concorde has the leading franchise in a market with tremendous growth opportunities. Their hardware systems are an excellent complement to the PET isotopes that we offer our research customers," said Thomas J. Hook, president of CTI Solutions and senior vice president of CTI Molecular Imaging.

"More importantly, this is another step in CTI Molecular Imaging's evolution toward a focus on developing new molecular probes and biomarkers for the diagnostic market," Hook said. "We intend to augment our own internal development of these compounds through partnerships with the leading pharmaceutical research organizations in the world."

For more information, visit:
Jun 2004
Concorde MicrosystemsCTI Molecular Imagingmolecular imagingNews & FeaturesPETpositron emission tomography

back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.